Nationale Nederlanden PTE – the largest institutional investor in the CEE region, joins the shareholder base of multiQure

7 August

2026

Nationale Nederlanden PTE – the largest institutional investor in the CEE region, joins the shareholder base of multiQure

Esaliens TFI – one of the leading independent institutional investors in Poland, joins the shareholder base of multiQure

6 August

2026

Esaliens TFI – one of the leading independent institutional investors in Poland, joins the shareholder base of multiQure

Pure Biologics has changed its name to multiQure and completed the transformation of its business model

4 August

2026

Pure Biologics has changed its name to multiQure and completed the transformation of its business model

Changes to the governing bodies of the future multiQure Company reflecting its business transformation

1 July

2026

Changes to the governing bodies of the future multiQure Company reflecting its business transformation

multiQure project will raise PLN 50 million for delivery of key development milestones for RNAi therapy for Huntington’s disease

23 June

2026

multiQure project will raise PLN 50 million for delivery of key development milestones for RNAi therapy for Huntington’s disease

FDA explains the Regulatory Path for Gene Therapies. An Opportunity for the multiQure Project

19 June

2026

FDA explains the Regulatory Path for Gene Therapies. An Opportunity for the multiQure Project

1
2
3
4
5
6
7
8
9
…
13

25 January

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/2/20 25.01.2020

21 January

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/1/20 21.01.2020

15 November

2019

Zapytanie Ofertowe – PB/MAGBBRIS/0/6/19 15.11.2019

5 November

2019

Zapytanie Ofertowe – PB/MAGBBRIS/0/5/19 05.11.2019

1
2

We use cookies to give you the best browsing experience, site traffic analysis, and advertisement management.